» Articles » PMID: 26150734

Successful Creation of an Anemia Management Algorithm for Hemodialysis Patients

Overview
Publisher Dove Medical Press
Specialty Nephrology
Date 2015 Jul 8
PMID 26150734
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Several anemia guidelines for hemodialysis patients have recommended a target hemoglobin (Hb) range of 10-12 g/dL. However, maintaining Hb values continuously within a narrow target has been difficult, and there has been no generally accepted anemia management algorithm for hemodialysis patients.

Methods: In our study, we created an anemia management algorithm that considers the length of erythrocyte lifetimes, focuses on the combination of erythropoiesis-stimulating agent management and iron administration, and prevents iron deficiency and overload. Our algorithm established a target Hb range of 10-12 g/dL.

Results: We evaluated our algorithm in 49 patients for 6 months. The mean Hb values were approximately 11 g/dL during our study period. The percentage of patients in the target Hb range of 10-12 g/dL increased from 77.6% (38 of 49) at baseline to 85.7% (42 of 49) at 4-6 months. Throughout monthly regular blood tests during 1-6 months after we introduced our algorithm, Hb values remained within the target range in 55.1% (27 of 49) of patients. The standard deviation of Hb values significantly decreased at 5 and 6 months (P=0.013 and P=0.047, respectively; 1 g/dL at 0 month, 0.7 g/dL at 5 months, and 0.7 g/dL at 6 months). Our algorithm also succeeded in suppressing cumulative doses of iron (≤800 mg) and decreasing the ferritin values significantly (P=0.011). There were no significant differences in erythropoiesis-stimulating agent doses between 0 and 6 months (P=0.357).

Conclusion: Our anemia management algorithm successfully increased the number of patients in the target Hb range, significantly decreased the Hb standard deviation, suppressed cumulative doses of iron, and decreased ferritin values. These results suggest a better prognosis for hemodialysis patients. Further studies are required to evaluate our algorithm.

Citing Articles

Development and Validation of a Treatment Algorithm for Osteoarthritis Pain Management in Patients With End-Stage Kidney Disease Undergoing Hemodialysis.

Mohsen M, Feldberg J, Abbaticchio A, Jassal S, Battistella M Can J Kidney Health Dis. 2024; 11:20543581241249365.

PMID: 38746016 PMC: 11092542. DOI: 10.1177/20543581241249365.


A pharmacist-managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial.

van den Oever F, Heetman-Meijer C, Birnie E, Vasbinder E, Swart E, Schrama Y Pharmacol Res Perspect. 2020; 8(4):e00628.

PMID: 32715653 PMC: 7383089. DOI: 10.1002/prp2.628.

References
1.
Hasuike Y, Nonoguchi H, Tokuyama M, Ohue M, Nagai T, Yahiro M . Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study. Clin Exp Nephrol. 2010; 14(4):349-55. DOI: 10.1007/s10157-010-0288-x. View

2.
Cotter D, Stefanik K, Zhang Y, Thamer M . Improved survival with higher hematocrits: where is the evidence?. Semin Dial. 2004; 17(3):181-3. DOI: 10.1111/j.0894-0959.2004.17317.x. View

3.
Portoles J, de Francisco A, Gorriz J, Martinez-Castelao A, Lopez-Gomez J, Arias M . Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study. Kidney Int Suppl. 2008; (111):S82-7. DOI: 10.1038/ki.2008.524. View

4.
Brier M, Gaweda A, Dailey A, Aronoff G, Jacobs A . Randomized trial of model predictive control for improved anemia management. Clin J Am Soc Nephrol. 2010; 5(5):814-20. PMC: 2863987. DOI: 10.2215/CJN.07181009. View

5.
Eschbach J, Abdulhadi M, Browne J, Delano B, Downing M, Egrie J . Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989; 111(12):992-1000. DOI: 10.7326/0003-4819-111-12-992. View